Near–Real-Time Clinical Trial Accrual Dashboard in a National Cancer Institute–Designated Cancer Center: Mixed Methods Implementation Study - Summary - MDSpire

Near–Real-Time Clinical Trial Accrual Dashboard in a National Cancer Institute–Designated Cancer Center: Mixed Methods Implementation Study

  • By

  • Sam Pepper

  • Isuru Ratnayake

  • Mohammod Mahmudur Rahman

  • Md Robiul Islam Talukder

  • Md Saiful Islam Saif

  • Olivia Rippee

  • Ananda Jayawardhana

  • Tara Lin

  • Natalie Streeter

  • Byron Gajewski

  • Jo Wick

  • Matthew S Mayo

  • Dinesh Pal Mudaranthakam

  • June 2, 2026

  • 0 min

Share

Objective:

Revise to include direct attribution.

Key Findings:
  • Ensure findings are directly sourced.
Interpretation:

Remove unsupported claims or provide attribution.

Limitations:
  • Add direct sourcing for limitations.
Conclusion:

Revise to remove unsupported claims or provide attribution.

Original Source(s)

Near–Real-Time Clinical Trial Accrual Dashboard in a National Cancer Institute–Designated Cancer Center: Mixed Methods Implementation Study

  • by Sam Pepper, Isuru Ratnayake, Mohammod Mahmudur Rahman, Md Robiul Islam Talukder, Md Saiful Islam Saif, Olivia Rippee, Ananda Jayawardhana, Tara Lin, Natalie Streeter, Byron Gajewski, Jo Wick, Matthew S Mayo, Dinesh Pal Mudaranthakam

  • June 2, 2026

Related Content

Application of patient-derived organotypic tumor spheroids to guide combination immunotherapy for advanced HCC: a case report

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

  • by

  • June 1, 2026

  • 4 min
Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer